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Abstract 
Preeclampsia is a disease of pregnancy that affects approximately 3-5% of women with 
child. It is one of the primary causes of mortality in mothers and babies across the globe. 
The exact cause, pathogenesis, or disease progression is unknown. Therefore, there is no 
definition of which patients are at risk for developing preeclampsia and what can work as 
a preventative measure. In high socioeconomic settings where there is good healthcare, 
standard treatment is established to manage the symptoms and decrease the progression 
of preeclampsia to eclampsia. However, in more rural, third-world settings of developing 
countries, caring for patients with preeclampsia is not a straightforward matter. Due to 
decreased access to health care, low economic status, and lack of education, preeclampsia 
is often seen yet seldom treated among this population. The discussion below addresses 
several possible pathophysiological processes of preeclampsia, as well as potential risk 
factors. The standard treatments of care are then discussed, followed by the evaluation of 
studies regarding alternative treatments for preeclampsia. The importance of screening 
pregnant women in developing nations is included. The discussion is concluded by a 
summary of what caring for preeclampsia in a third-world setting might look like for a 
missionary nurse. 
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A Practical Understanding of Preeclampsia for a Nurse in a Third-World Setting 
Disease: this word, simply a summation of letters, is one that makes people shiver 
with horror and dread. Disease causes people to evaluate themselves and look deep into 
their hearts to what is the meaning and significance of their lives. As Warwick Anderson 
sums up all too well, disease brings into focus concerns on the way we live our lives, our 
relationships to community, our environment, the cosmos, and challenges us to explain 
the purpose of suffering (Anderson, 2000). Disease brings about even more confused 
questioning and evaluation when it touches the lives of infants and children. For this 
reason, illnesses that affect infants and the young are often given much consideration, 
research, and resources in order to give these children a greater chance to live life. 
However, as sickness and disease involve the tiny intricacies of creation our human 
minds can never fully comprehend, many diseases have no cure, or even a definitive 
cause. Preeclampsia is just such a disease. Much research has been poured into searching 
for a cause for this disease of pregnancy, so a cure might be discovered. However, 
research is no closer to preventing preeclampsia than when it started. 
What is Preeclampsia? 
Preeclampsia is a pregnancy-specific disease process that impacts approximately 
3-5% of all births. It is one of the primary causes of maternal, fetal, and neo-natal 
mortality, particularly in low socioeconomic settings and third-world countries (Mol et 
al., 2016). Traditionally, it is diagnosed when a pregnant woman presents with symptoms 
of hypertension and proteinuria. If preeclampsia continues untreated, patients often 
advance to eclampsia, experiencing severe complications. These complications often 
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involve seizures, liver rupture, pulmonary edema, stroke, or kidney failure (Mol et al., 
2016). Preeclampsia also affects the growth of the baby, as it affects uterine perfusion. 
Due to hypertension involved in preeclampsia, blood flow to the fetus is altered, leading 
to fetal growth restriction and preterm birth, either spontaneous or through iatrogenic 
delivery. In addition to impacting the fetus during pregnancy, children who are born to 
mothers with preeclampsia can be permanently impacted as they have a high risk of 
bronchopulmonary dysplasia and cerebral palsy (Mol et al., 2016). These complications 
and others are caused by altered blood flow to the fetus during pregnancy and by preterm 
birth, as many preterm neonates are small for gestational age. 
Diagnostic Criteria 
The classic diagnostic criteria for a pregnant woman with preeclampsia were 
established by the International Society for the Study of Hypertension (ISSHP) in 2014. 
The ISSHP defined preeclampsia as de-novo, or new, hypertension that presents after 20 
weeks gestation combined with protein in the urine (>300 mg/day), neurological or 
hematological complications, maternal organ dysfunction, renal insufficiency, 
uteroplacental dysfunction, liver involvement, or fetal growth restriction (Mol et al., 
2016). As preeclampsia has many different presentations of the disease, the definition has 
been changed to no longer require proteinuria in the definition. Therefore, preeclampsia 
can now be split into two separate categories: proteinuric and non-proteinuric. 
Hypertension is defined as a systolic blood pressure that is higher than 140 mmHg, or a 
diastolic blood pressure greater than 90 mmHg. To be diagnosed with hypertension, the 
patient must meet these qualifications at two different blood pressure readings that are 
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taken at least 4-6 hours apart. The patient should be seated and in an upright position, or 
in a left lateral recumbent position (Mol et al., 2016). Whereas hypertension is very 
typical of preeclampsia, proteinuria is not always a clear indicator of the disease. Women 
with proteinuria tend to have high antenatal blood pressures, deliver at an earlier stage of 
gestation, and often need an operative delivery (Mol et al., 2016). 
Pathophysiology of Preeclampsia 
The exact pathophysiological mechanisms that produce the clinical symptoms of 
preeclampsia are unknown. However, there have been numerous conjectures on how the 
disease progresses at the tissue level. It is thought the clinical symptoms of the disease 
during pregnancy represent later stages of the disease progression. Therefore, the 
pathophysiological changes in the body most likely begin taking place long before it is 
realized. The pathology of preeclampsia is thought to most likely originate in the placenta 
during the development of the uteroplacental circulatory system. One reason for this 
thought is that the delivery of the fetus and the placenta at birth is the one and only cure 
found for the disease process (Moncrieff, 2018). Therefore, since the disease process is 
resolved by the delivery of the baby and the placenta, it most likely starts at the beginning 
stages of gestation.  
Alteration in Angiogenesis 
Under normal circumstances in the body of the mother, the establishment of 
uteroplacental circulation involves maternal spiral arteries transforming from small-
diameter, high resistance arteries into low-resistance, high-volume vessels that can fully 
perfuse the intervillous space. This transformation begins at approximately 8-10 weeks 
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gestation, when cytotrophoblasts enter into the wall of the uterus and take on some of the 
characteristics of the cells that make up blood vessels (Moncrieff, 2018). 
Cytotrophoblasts do this by aiding in increasing the levels of proteins that make up 
endothelial and smooth muscle cells, and slightly decreasing levels of proteins that make 
up epithelial cells. This leads to cytotrophoblast formation that looks similar to an 
endothelial, or smooth muscle phenotype. This results in the ‘vascular mimicry’ that is 
seen in preeclampsia as cytotrophoblasts invade the uterine wall. As they travel through 
the stroma of the uterine wall, these cells cross into walls of the maternal spiral arteries 
and move up these blood vessels. As the cytotrophoblasts work their way up the spiral 
arteries, they replace the endothelial lining and some parts of the smooth muscle layer 
(Moncrieff, 2018). The loss of these muscle layers in the maternal spiral arteries changes 
the vessels from thin, small-diameter vessels into high-capacity, low-resistance arteries. 
Since the cytotrophoblasts remove many neuromuscular and baroreceptor components of 
these spiral arteries, the vessels are no longer very responsive to modulators, allowing 
these arteries to sustain a low-velocity, but high-volume flow to the intervillous space 
(Moncrieff, 2018). In this way, the mother’s body naturally transitions to providing 
enough blood flow to the developing fetus. 
In preeclampsia it is thought this transformation of the spiral arteries remains 
incomplete. In the pathology of preeclampsia, cytotrophoblasts are unable to fully 
migrate into the maternal spiral arteries. Therefore, many of the mother’s blood vessels 
are incompletely transformed or are not transformed at all (Moncrieff, 2018). In normal 
uteroplacental circulatory transformation, the changes to the spiral arteries extend into the 
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myometrium of the arteries. In preeclampsia, however, the myometrial portion of many 
of the vessels is unaltered. Therefore, mothers with preeclampsia retain arteries with thick 
muscular walls and a highly functioning adrenergic nerve supply. These vessels remain 
small-diameter, high-resistance arteries that provide a low-volume, high-pressure flow to 
the placenta (Moncrieff, 2018). In addition, intact neurological components and 
baroreceptors allow the nerves of these vessels to greatly impact the blood flow to the 
placenta. This overall incomplete transformation of the maternal spiral arteries causes 
decreased perfusion to the placenta and a high blood pressure flow that is subject to 
vasoconstriction in response to the mother’s systemic responses. This leads to placental 
ischemia and lack of perfusion, and therefore oxidative stress. This is thought to result in 
the release of cytokines and anti-angiogenic proteins into the mother’s blood, which 
alters vascular growth and permeability (Moncrieff, 2018). In the preeclamptic mother, 
the high-pressure blood flow that perfuses the intervillous space leads to 
syncytiotrophoblast particles being released into the mother’s blood. These by-products 
of placental stress cause the maternal signs of endothelial damage, increased vascular 
resistance, and increased coagulation and hemostasis (Moncrieff, 2018).  
Alterations in Immune Adaptation 
Yet another theory on the pathogenesis and development of preeclampsia is based 
on the significant and detailed immune adaptations that take place in the mother’s body 
during pregnancy (Alrahmani & Willrich, 2018). The goal of these immune adaptations is 
to maintain a competent immune system in the mother in order to fight off disease, while 
preventing rejection of the growing fetus. This complex phenomenon is known as 
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maternal-placental immune tolerance. The changes that take place in the mother’s body 
are multi-faceted. The immune response cytokine profile gradually changes from T-
helper 1 to T-helper 2. The activation of T cells in general is suppressed overall, and with 
the help of the enzyme indoleamine-2,3-dioxygenase, the production of natural killer 
cells is decreased and substituted with the manufacturing of macrophages and 
syncytiotrophoblasts. The amount of granulocytes in the mother’s blood stream increases 
at the same rate as the levels of acute-phase proteins. In summary, the innate immune 
system is enhanced in pregnancy, while components of the adaptive immune system are 
suppressed. The complement system is also a critical part of the innate immune system 
(Alrahmani & Willrich, 2018). The complement system acts to regulate tissue 
homeostasis. There are three separate pathways that play a part in the complementary 
system. These pathways are the classical, alternative, and lectin/mannose-binding 
pathways. Each pathway is induced by different threats to the body’s homeostasis or 
pathogenic agent. The classic pathways are induced by an antigen-antibody immune 
complex or a C-reactive protein (CRP). The alternative pathway is always active to some 
degree at low levels, as it plays a role in the general health and immune processes of the 
body. Finally, the lectin/mannose-binding pathway is activated by mannose-containing 
bacteria (Alrahmani & Willrich, 2018). All three pathways converge into a C3 mediated 
loop. The activation of the enzyme C3 by C3 convertases leads to the binding and tagging 
of foreign cells or bacteria. This is how the complement pathways regulate the innate 
immune system.  
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One well-accepted theory regarding the pathogenesis of preeclampsia as related to 
the immune system is that of immune maladaptation. It is the idea that the normal 
immunologic changes a mother’s body goes through during pregnancy are altered by a 
factor in the placenta that leads to an increased adaptive immune system and decreased 
changes in the innate immune system. This therefore would lead to an increased immune 
response against the fetus, which is an allograft that contains paternal antigens. The 
innate immune system of the mother would experience only slight alterations, leading to 
a heightened immune response during pregnancy. This would cause inflammation, altered 
angiogenesis, and increased endothelial activation that are seen in preeclampsia 
(Alrahmani & Willrich, 2018). Let it be understood, however, the precise 
pathophysiological mechanisms of preeclampsia and their effect of endothelial 
dysfunction and hypertension are still unclear and undergoing extensive research. 
Risk Factors for Developing Preeclampsia 
As there is no definitive cause for preeclampsia, treating, preventing, and 
identifying at-risk populations often is a complicated matter. In a study conducted in the 
U.S. on clinical risk factors for preeclampsia in the 21st century, two thousand six 
hundred thirty-seven women were included in the analysis (Pare et al., 2014). Over the 
process of the study, seven hundred ninety-three were excluded for the following reasons: 
sponsor request or decision, protocol deviation, participant missed two study visits or 
more, participant withdrew consent, incomplete delivery data, spontaneous or induced 
termination of pregnancy, or transfer of care. The women involved in the study were 
recruited at three different hospitals from three different areas of the country (Pare et al., 
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2014). Out of the women who finished the study, one hundred sixty-five (6.2%) had a 
preexisting case of chronic hypertension. The rate of hypertensive disorders that 
developed over the progression of pregnancy were as follows: three hundred seventy-
eight (14.3%) developed gestational hypertension, two hundred thirty-seven (9.0%) 
developed preeclampsia, one hundred ninety-four (7.4%) developed severe preeclampsia, 
thirty-nine (1.5%) developed a syndrome consisting of hemolysis, elevated liver 
enzymes, and low platelet count (HELLP syndrome), and one patient (0.04%) progressed 
to eclampsia. The mean gestational delivery age of the patients who did not develop 
preeclampsia was 38.8 weeks (standard deviation of 2.0), while for women who did 
develop preeclampsia, the mean gestational age at delivery was 37.0 weeks (standard 
deviation of 2.7) (Pare et al., 2014). In the discussion of this study, it was found many of 
the previously and commonly reported risk factors for preeclampsia proved to be true. 
Medical conditions such as chronic hypertension and diabetes have been shown to be 
potential risk factors for preeclampsia. Multiple gestation, African American race, use of 
assisted reproductive techniques, prior cases of preeclampsia, nulliparity, and obesity 
were also confirmed to be independent predictors of preeclampsia and severe 
preeclampsia. However, in contrast to previous studies performed, the factor of advanced 
maternal age was not associated with an increased risk for preeclampsia. In addition to 
this, being overweight or obese was the most prevalent risk factor for both mild and 
severe preeclampsia in the patient population involved in the study (Pare et al., 2014). 
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Preventative Risk Factors of Preeclampsia 
This study particularly highlighted risk factors that should help in affecting and 
guiding prevention of preeclampsia in a health care perspective. Until recently, 
preeclampsia has been treated from a purely pharmacological standpoint since not much 
is known about it. This is partly resultant to clinical prediction rules and scoring having 
often been limited to nonmodifiable risk factors such as medical conditions, nulliparity 
and race. Therefore, there was not much that could be done to prevent preeclampsia. 
However, the above discussed study highlights one modifiable risk factor that represented 
the greatest risk factor: obesity. Since it is modifiable, preventive measurements should 
be implemented. Given the obesity-attributable risk in the study, great efforts to prevent 
preeclampsia should focus on prevention of obesity in women who are pregnant or even 
of reproductive age. The percentage of cases of preeclampsia in the study that could be 
associated with obesity was 64.9% of all the cases of preeclampsia and severe 
preeclampsia (Pare et al., 2014). From a clinical perspective, the results of the study 
highlight the importance of discussing weight with women who are of reproductive age 
and possibly including a weight reduction component in pre-conceptional counseling for 
obese and overweight women. This is due to results suggesting that even a modest 
reduction in BMI before conception could drastically decrease the individual’s risk of 
preeclampsia (Pare et al., 2014). 
Treatment for Preeclampsia 
As has been previously mentioned, much of the focus of treating preeclampsia has 
been on pharmacologic treatment over the years. Since preeclampsia’s primary trait is 
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hypertension, the National High Blood Pressure Educations Program (NHBPEP) 
Working Group Report has focused on targeting high blood pressure treatment in 
preeclamptic patients. As summarized earlier, mild hypertension is a systolic blood 
pressure (SBP) of 140-150 mmHg or diastolic blood pressure (DBP) of 90-109 mmHg.  
Severe hypertension is defined as an SBP >160 mmHg or DBP of >110 mmHg (Berzan, 
Doyle, & Brown, 2014).  
Standard Treatments of Preeclampsia 
Guidelines for treatment according to the American College of Obstetricians and 
Gynecologists (ACOG) do not recommend antihypertensive medication for mild 
preeclampsia (SBP < 160 mmHg or DBP <110 mmHg). However, antihypertensive 
therapy is recommended for women with preeclampsia who have a sustained SBP of 
>160 mmHg or DBP of >110 mmHg (Berzan et al., 2014). Although this disease is one 
of the most common complications of pregnancy all over the world, there are a limited 
number of medications that are used regularly as standards of treatment. 
Methyldopa and Labetalol. First-line agents for hypertension in preeclamptic 
patients include methyldopa and labetalol. Methyldopa is the drug of choice for 
hypertension in pregnant women, as its safety and efficacy have been shown through 
many studies. There are some concerns with side effects of depression, hepatic 
disturbances, and hemolytic anemia. It also may not lower blood pressures adequately or 
fast enough for some preeclamptic patients; therefore, methyldopa should not be used in 
emergent situations (Berzan et al., 2014). Labetalol is also a first line therapy. Its safety is 
similar to the above-mentioned medication, but labetalol may often be more efficacious 
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than methyldopa. However, it may be associated with possible fetal growth restriction, 
and when given in large doses, neonatal hypoglycemia may be seen. Labetalol then is not 
the drug of choice over methyldopa due to the side effects (Berzan et al., 2014). Second-
line agents for hypertension in preeclamptic patients include nifedipine, verapamil, and 
clonidine. For emergency treatment in preeclampsia, intravenous (IV) hydralazine, 
labetalol, and oral nifedipine may be used (Berzan et al., 2014). 
Magnesium Sulphate. Magnesium sulphate also plays a very crucial role in the 
management of preeclampsia and eclampsia. For more than a century, magnesium 
sulphate (MgSO4) has been the anticonvulsant of choice to prevent and control eclamptic 
fits. Historically, the total dose of magnesium sulfate used in the treatment of 
preeclampsia and eclampsia would be gradually increased from 2g/24 hours to as high as 
54 g/24 hours with the belief the increase in titration would increase the clinical efficacy 
(Okusanya et al., 2015). All studies have shown convulsions are controlled well with 
magnesium sulphate, despite the considerable alterations in the regimen, route of 
administration, and total dosage used (Okusanya et al., 2015).  
The goal in the administration of magnesium sulphate is to achieve physiological 
magnesium (Mg2+) homeostasis in the patient. A type of cation, Mg2+ is found all 
throughout the body. It works in the activation processes of many enzymes, including 
those of energy metabolism. It is critical cation in the production of ATP, therefore 
playing a crucial part in the neurological stability of a patient. Women who are pregnant 
generally maintain normal levels of Mg2+, with only minor fluctuations over the forty 
weeks of gestation. In preeclampsia, however, pregnancy often continues with normal 
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Mg2+ levels until generally the 32nd and 33rd weeks of gestation. This cation’s levels 
decline at this stage until delivery, with hypomagnesemia at delivery seen in 
preeclampsia (Chiarello et al., 2018).  
Magnesium sulphate is an inorganic salt that is administered for these patients. 
This salt contains Mg2+, oxygen, and Sulphur. Free Mg2+ concentration in maternal 
blood is 0.75 mmol/L and 0.83 mmol/L in fetal blood in normal pregnancies. However, in 
preeclamptic pregnancies, the value in maternal blood decreases to 0.66 mmol/L and 
increases to 1.01 mmol/L in fetal blood (Chiarello et al., 2018).  The exact impact of the 
increased of Mg2+ levels in fetal blood is unknown at the time, as there is not a clear 
explanation for the accumulation of Mg2+. It is universally acknowledged the beneficial 
effects of Mg2+ administration are unparalleled, as they mitigate the potential and 
associated complications of preeclampsia. However, there is not a clear understanding as 
to the potential mechanisms of action of the cation. There are many suggestions as to how 
magnesium sulphate alters the fetoplacental vascular function. These include the 
magnesium sulphate impacting altered function of Mg2+ transporters, membrane 
receptors, inadequate generation of nitric oxide (NO), and an inflammatory and oxidative 
state (Chiarello et al., 2018).  Parenteral administration of Mg2+ salts works primarily for 
the patient with severe preeclampsia to guard prophylactically against eclampsia and 
seizures. Although the specific mechanism of Mg2+ is not understood in preeclampsia, 
studies show that lower Mg2+ levels are seen in the red blood cell membranes of patients 
with preeclampsia in contrast to women with normal pregnancies (Chiarello et al., 
2018).This consistent trend in altered Mg2+ levels in both mother and baby is considered 
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to be a predisposing factor in the pathogenesis and development of preeclampsia. Clinical 
practice dictates that maintaining a maternal plasma Mg2+ level higher than the normal 
range of 0.75-1.0 mmol/L is required to reduce the chance of advancing from 
preeclampsia to eclampsia (Chiarello et al., 2018). In addition to this, overall levels of 
Mg2+, calcium, creatinine, and proteins, as well as maternal bodyweight, are crucial to 
monitor and keep at safe levels in order to achieve a safe and effective delivery (Chiarello 
et al., 2018). 
In planning care for a pregnant mother, antihypertensive medication and 
magnesium sulphate are the standards of care. However, these standards of care are those 
that have been determined to work in first world countries in the presence of primary 
health care providers. In many areas of the world where there are no primary health 
providers, there are great challenges in the prediction, prevention, and management of 
preeclampsia (Osungbade & Ige, 2011). The cost and accessibility of such medications as 
those which are generally prescribed for treatment of preeclampsia make treatment and 
management of the disease very difficult. Treatment in these countries consists of the 
following: prenatal care, a timely diagnosis, proper management, and a timely delivery. 
The impact of preeclampsia is felt significantly in low income and third world areas since 
medical interventions are often ineffective due to the late identification and treatment of 
cases of preeclampsia (Osungbade & Ige, 2011). 
Screening for Preeclampsia 
Prevention of this disease process requires availability of predictive measures for 
those at a high risk for developing the disorder. Although countless clinical and 
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biochemical tests have been devised for those at risk, most remain quite unrealistic for 
common use in developing countries. At the current time, there is no single reliable and 
cost-effective screening test for preeclampsia that can be recommended for use in 
developing countries (Osungbade & Ige, 2011).  
Screening in a Third-World Country 
The primary way to efficiently and accurately screen pregnant women for 
preeclampsia is the establishment of easily accessible, functional health care systems. In 
the majority of developing countries, particularly in areas like Africa and Southern Asia, 
there are three levels of delay that result in limited health care access (Osungbade & Ige, 
2011). The first is delay in the decision to seek care. This delayed response at the patient 
level is often a result of insufficient information on signs and symptoms of the disease 
process, as well as inadequate information on where and when to seek help from a 
facility. Poverty, corrupt power, and the rising cost of health care lead to often fatal 
delays in care seeking (Osungbade & Ige, 2011). The second level is delay in reaching 
the health care facility. Lack of access to quality care is often one of the main obstacles to 
reducing maternal and neonatal mortality in low income countries. This is often in part 
due to the placement of the health care facilities in relation to the location of villages, 
distance, and lack of transport to the areas where the health care providers are located. 
For example, in Nigeria, up to 50% of rural women live over 5 kilometers from the 
nearest hospital. Most of these women have no way of reaching the hospital except by 
walking – even when they are in labor. Therefore, most of the pregnant population of 
these villages do not make it to the hospital during delivery. For a woman with 
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preeclampsia, this lack of treatment could progress to eclampsia, leading to death for both 
the mother and baby. This could all take place without the nearest health care facility 
knowing anything about the mother and her baby (Osungbade & Ige, 2011). Finally, the 
third level of delay is delay in health service provision. In many health facilities in the 
third world setting, health care insurance is in the teething stage, making it impossible for 
both the poor and the insured to obtain care during emergent situations. Identified barriers 
include the attitudes of many of the health service providers as well as the perceived poor 
quality of care. These barriers are increased by the lack of trained personnel and the 
extreme lack of equipment and supplies. In many cases of preeclampsia in a third world 
hospital, studies have shown magnesium sulphate wasn’t routinely administered if it was 
available. Another consideration is that the use of magnesium sulphate is often limited 
solely to teaching hospitals. The overall lack of availability of the drug and appropriate 
health personnel as well as equipment to administer it frequently raises obstacles for 
treating preeclamptic women (Osungbade & Ige, 2011). 
Using CLIP in a Rural Setting. Globally, hypertensive diseases of pregnancy, 
two of the top ones being preeclampsia and eclampsia, are the primary causes of maternal 
and neonatal mortality. Therefore, managing preeclampsia and eclampsia in less modern 
and first world settings is a priority when evaluating world-wide health initiatives for 
mothers and babies around the world (Khowaja et al., 2015).  Hypertensive disorders of 
pregnancy (HDP), which include pre-eclampsia and eclampsia, complicate over 10 
million pregnancies worldwide each year. This results in 76,000 maternal and 500,000 
neonatal deaths. The large majority of these deaths (>99%) take place in low- and 
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middle-income countries (LMICs), particularly in South Asia and in Sub-Saharan Africa 
(Khowaja et al., 2015). The Community Level Interventions for Preeclampsia (CLIP) 
trial evaluates a package of care that could be applied at a community level in addition to 
being implemented through hospitals and primary health care centers. This package 
directly seeks to address and intervene against the three levels of delay mentioned above 
(Osungbade & Ige, 2011). If applied appropriately, maternal and perinatal complications 
and potential deaths could be reduced drastically in village communities and the third 
world setting. As discussed above, management of preeclampsia mainly focuses on 
interventions in a primary health facility. These include antihypertensive therapies, 
anticonvulsant therapies, and timed deliveries. However, thousands of women in LMICs 
are unable to reach facilities that monitor and provide treatment during delivery for those 
with preeclampsia. These women in hard-to-reach areas suffer disability and often lose 
their lives due to a lack of resources for screening and identification of HDP as well as 
triage and transport availability. In a first world country, these clinical processes are at 
the reach of almost every woman, allowing a usually safe and monitored delivery 
(Khowaja et al., 2015). 
How CLIP Works. The goal of the CLIP trial is introducing evidence-based 
interventions at community levels through the availability and presence of primary health 
care providers. Specifically, the CLIP intervention involves three levels: 
I. Community engagement 
II. Provision of HDP-oriented antenatal care through household visits 
III. Use of the CLIP package for women with a CLIP ‘trigger’ 
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(Khowaja et al., 2015) 
The community engagement level seeks to include all women, particularly those 
who are currently pregnant or could become pregnant. It also includes the decision 
makers of the households (husbands, father-in-laws, or brothers) and community leaders. 
Community engagement involves teaching these groups about preeclampsia, its origins, 
signs, symptoms, and potential consequences. It seeks to inform the community about 
potential cost for transport and treatment and what that would look like (Khowaja et al., 
2015). The second step, provision of HDP-oriented antenatal care, is done through 
household visits to pregnant women. Community healthcare providers (cHCPs) would 
travel from home to home with the proper equipment, screening women for potential risk 
factors or symptoms of preeclampsia or other HDPs. Since the women and families will 
have been previously informed as to what signs and symptoms to look for, in addition to 
the potential complications that could arise if left untreated, this step is expected to be 
received with cooperation and understanding since community involvement would 
already be achieved (Khowaja et al., 2015). Finally, the third step aims to provide a CLIP 
package for women who had a CLIP ‘trigger.’ This CLIP package will include oral 
antihypertensive therapy or intramuscular magnesium sulphate. Administration of this 
package will be accompanied by appropriate education as to the use of these medications. 
Appropriate referrals to a comprehensive emergency obstetric care facility will also be 
provided, in addition to what transport to the facility would require (Khowaja et al., 
2015). The cHCPs would regularly assess and check up on these women approximately 
every 4 weeks at minimum. These visits could be done either in the home, or at a primary 
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health care facility, if there is one close by. The cHCPs are trained specifically to screen 
the women for symptoms, using culture and country specific pictograms. They also take 
the woman’s blood pressure each visit, noting trends or signs of hypertension. The 
cHCPs also check urine for protein at the first visit using a dipstick, and then on 
following visits if the patient’s systolic blood pressure is over 140 mmHg. This screening 
process allows for consistent care and early diagnosis of preeclampsia. Women with 
preeclampsia can then be referred to facilities with specific care or given CLIP packets to 
take during pregnancy (Khowaja et al., 2015). 
Alternative Treatments for Preeclampsia to Use in Third-World Setting 
In addition to introducing CLIP interventions in rural and third world settings to 
proactively screen and manage patients with preeclampsia, there has been a significant 
amount of research performed on alternative therapies and treatments, other than that of 
antihypertensive medications and magnesium sulphate (Atallah et al., 2017).  
Preventing Preeclampsia with Aspirin 
Aspirin is currently the most widely prescribed medication for the prevention of 
cardiovascular diseases and complications. However, aspirin may also be indicated for 
usage during pregnancy for women who have preeclampsia. Large meta-analyses have 
reviewed individual patient data as well as anonymous surveys, demonstrating aspirin is 
often very effective in preventing preeclampsia in those patients who are at a high risk for 
developing the disease (Atallah et al., 2017). Aspirin has been shown to be particularly 
helpful in preventing preeclampsia among those patients who have a history of 
preeclampsia. Guidelines regarding the use of aspirin for preeclampsia vary greatly from 
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country to country. Types of screening, target population, and the prescribed dosage of 
aspirin in preventing preeclampsia are still matters of heated debate (Atallah et al., 2017). 
Pathophysiology. To understand the use of aspirin for the treatment of 
preeclampsia, the pathophysiology of the disease must be reviewed. In this disease, the 
platelet TXA2 increases significantly, while prostacyclin levels drop sharply due to 
changes in the mother’s body during pregnancy. Around the 13th week of gestation in 
women who are at a high risk for preeclampsia, this imbalance of platelet TXA2 and 
prostacyclin is visible. TXA2/PGI2 imbalance can be reversed within 2 weeks of 
treatment with a low dose aspirin regimen (Atallah et al., 2017). Aspirin acts by 
inhibiting TXA2 secretion, and thus platelet aggregation. However, aspirin doesn’t alter 
the secretion of endothelial prostacyclin, correcting the increase of TXA2 and decrease of 
PG12. This correction favors maternal systemic vasodilation, resulting in decreased 
hypertension and increased blood flow to the uterus and therefore the fetus. More recent 
understanding of the impact of angiogenic factors on placental hemodynamics in women 
with preeclampsia has led to the study of the impact of aspirin on the secretion of these 
factors in the placenta (Atallah et al., 2017). In situations of decreased blood flow, and 
therefore hypoxic conditions for the fetus, aspirin inhibits the production of sFlt-1 in 
human trophoblasts. This produces proangiogenic results. The factor sFlt-1 is the 
common type of vascular endothelial growth factor (VEGF) seen in pregnancy. When it 
binds to circulating placental growth factor and other types of VEGFs, it behaves as a 
concentrated anti-angiogenic factor. Patients with preeclampsia or who have a history of 
preeclampsia have high levels of sFlt-1 in their plasma. Therefore, it is thought that sFlt-1 
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is responsible for the angiogenic imbalance seen in the pathophysiology of preeclamptic 
patients (Atallah et al., 2017). Since aspirin binds to this factor, angiogenic growth is 
promoted, increasing blood flow to the developing fetus and decreasing hypertension in 
the mother. 
Controversy with the Use of Aspirin. Although numerous and continual studies 
have been performed on the potential use of aspirin in preeclamptic mothers, the debate 
continues. Even though aspirin does decrease some of the anti-angiogenic results of the 
factors in the patient with preeclampsia, aspirin also crosses the placental barrier and 
alters TXA2/PGI2 balance and platelet aggregation of the fetus (Atallah et al., 2017). 
After it perfuses into the placental cotyledon, aspirin transfers over into the fetal-
placental circulation during the first 5 minutes. Laboratory tests performed on blood from 
the umbilical cord of pregnant women who are taking low-dose aspirin reveal a sharp 
drop in platelet TXA2. Although this acts to decrease hypertension in mothers, there have 
been sporadic cases reported of intracranial hemorrhage in premature infants and low-
weight fetuses, in addition to early closure of the arterial canal (Atallah et al., 2017). 
Therefore, it is presumed that aspirin treatment may lead to a decrease in fetal platelet 
aggregation, resulting in an increased chance of utero cerebral hemorrhage. Low dose 
aspirin administration doesn’t seem to introduce a teratogenic risk in the first trimester, 
but it has been advised aspirin treatment should be discontinued around 36 weeks of 
gestation to decrease risks of hemorrhage in mothers and babies (Atallah et al., 2017). 
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Preventing Preeclampsia with Calcium Supplements 
Pathophysiology. Yet another possible alternative treatment for preeclampsia that 
has been investigated is calcium. Preeclampsia is often characterized by inflammation 
cascades as well as endothelial activation (DeSousa et al., 2016). This results in the 
multi-organ disease that we see in pregnancy. A placental factor that consists of deported 
trophoblastic debris is increased in the blood of mothers with preeclampsia. Deported 
trophoblastic debris is seen in the blood of mothers in all pregnancies, but increased 
levels in preeclamptic mothers is suggested to be from the nature of increased cell death 
in the syncytiotrophoblast. In normal pregnancies, the death of syncytiotrophoblasts are 
more apoptosis-like, while in preeclampsia, cell death is more necrotic (DeSousa et al., 
2016).  Other studies point to placental factors that are related to the process of 
angiogenesis, such as sFlt-1, PIGF, and sEndoglin, are involved in the pathogenesis of 
preeclampsia. Studies show that levels Flt-1 in the maternal blood flow are directly 
proportional to the amount of trophoblastic debris. This trophoblastic debris from a 
placenta that is preeclamptic has been treated with preeclamptic sera that is dangerous 
and toxic. When this trophoblastic debris is phagocytosed, it leads to endothelial cell 
activation and increased levels of inflammatory cytokines (DeSousa et al., 2016). Both 
processes are seen in those with preeclampsia. 
The alternative treatment to prevent or reduce the risk of preeclampsia is to 
provide an antenatal treatment of calcium supplementation. There is currently limited 
evidence of low-dose calcium supplementation reducing preeclampsia, requiring larger 
and higher quality trials to be performed before a definitive result is can be determined 
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(DeSousa et al., 2016). Calcium has been shown in these limited studies to decrease the 
activation of endothelial cells in the in vitro setting when the activation of these cells was 
caused by necrotic trophoblastic debris, preeclamptic sera, and interleukin (IL)-6. These 
factors all are seen in increased levels in preeclamptic patients, leading to increased 
activation of endothelial cells. Studies have been specifically targeted at whether the 
addition of a calcium supplement at clinically acceptable doses would prevent or decrease 
the activation of endothelial cells that were induced by toxic levels of trophoblastic debris 
(DeSousa et al., 2016). 
Results of Studies. Results from a study which took blood samples from both 
preeclamptic women and normotensive pregnant women of the same gestation times 
were compiled, studying culture inserts into placental explant cells. The resulting 
endothelial cell activation was then closely monitored, after being treated by debris from 
trophoblasts. Results showed calcium supplementation decreased or prevented the 
activation of endothelial cells by the trophoblastic debris in the placenta from 
preeclamptic patients (DeSousa et al., 2016). When the trophoblastic debris from cells 
from a preeclamptic placenta were introduced, the expression of ICAM-1 by the cells was 
increased as well as the number of monocytes that adhered to the endothelial cells. This 
resulted in increased inflammation. However, when calcium was introduced to the 
endothelial cells, at the same time as the trophoblastic debris of preeclamptic cells, the 
increase in ICAM-1 and monocyte adhesion was reversed (DeSousa et al., 2016). 
Calcium supplementation also prevented activation of endothelial cells that was caused 
by increased levels of IL-1. These increased levels of IL-1 increased levels of cell-surface 
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endothelial ICAM-1. However, at the introduction of supplemental calcium treatment, 
this reactive chain was reversed. Therefore, in this vitro study, as in many others, it can 
be seen calcium supplements can decrease the activation process of endothelial cells in 
the presence of trophoblastic debris from the placenta of preeclamptic patients, as well as 
normal placenta that were treated with preeclamptic sera (DeSousa et al., 2016). This 
suggests the mechanism by which calcium acts in reducing the risk of a patient 
developing the disease of preeclampsia during pregnancy.  
Meta-analysis of many studies looking into calcium supplementation as a 
potential treatment for preeclampsia show calcium treatment decreases the risk of 
preeclampsia by about fifty percent (DeSousa et al., 2016). This is especially true in the 
case of women with previous low calcium intake levels. Calcium appears to exert its 
mechanism of action, at least in part, by decreasing endothelial action that is caused by 
the toxic trophoblastic debris from preeclamptic placenta. In this way, it seems to reverse 
one of the direct pathways that leads to the development of increased blood pressure and 
inflammation seen in preeclamptic patients. Anti-inflammatory effects appear to be the 
result of calcium supplementation (DeSousa et al., 2016). Although the direct cause and 
pathogenesis of preeclampsia is unknown, calcium supplementation appears to decrease 
the risk or at least the exacerbation of some of the pathways that lead into preeclamptic 
conditions.  
Conclusion 
For a third-world focused nurse, standard treatments and standards of care such as 
magnesium sulphate may not always be readily available. However, for women who have 
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a history of preeclampsia in past pregnancies or who have pre-gestational hypertension, 
supplemental calcium or an increase in high calcium foods may potentially decrease 
chances of developing the disease of preeclampsia. If not completely preventing the 
disease, calcium may decrease the intensity of the disease as it would decrease some of 
the inflammatory pathways. The use of aspirin could also be potentially considered as an 
alternative treatment for preeclampsia.  
The current interventions that have been studied and established to have the most 
clinical significance in diagnosing, preventing, and treating women with preeclampsia or 
eclampsia are diagnostics, transferring to a hospital, magnesium sulfate use, and cesarean 
section/labor induction (Goldenberg et al., 2014). Typically, diagnosis of preeclampsia 
using blood pressure screenings for high risk or hypertensive patients and screening for 
proteinuria have proved to be most helpful in determining which patients need further 
care as relates to preeclampsia. Either these patients can be transported to a hospital, or 
proper medical care can be brought into their area of residence to provide a timely and 
safe delivery through cesarean section or through induction of labor. Since the only 
determined cure for preeclampsia is the delivery of the baby, thereby ending this disease 
through the ending of the pregnancy, mothers with severe preeclampsia often need an 
induction of labor to ensure safety for both the mother and baby. However, this early 
delivery often leads to slightly preterm infants. This may necessitate the baby spending 
some time in the Neonatal ICU, requiring the mother and/or the baby to be sent to a 
nearby hospital. For preeclamptic mothers who can wait until their full gestation time is 
finished to deliver, magnesium sulfate can be brought in to be administered during the 
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delivery process. Preeclamptic mothers can also be taken to a hospital to have this 
treatment administered to delay the progression of preeclampsia to eclampsia, reducing 
both maternal and fetal mortality (Goldenberg et al., 2014). The highest priority, then, for 
the nurse in a third world culture providing treatment for pregnant mothers is to provide 
screening for this patient population. If proper screening is performed on all pregnant 
mothers, especially those at a high risk for preeclampsia that have a history of 
preeclampsia or who are obese, this will allow for early diagnosis and appropriate 
planning of treatment. Currently, there is not enough research completed on use of aspirin 
in prevention of preeclampsia to suggest that for standard of care. Although it cannot be 
decisively concluded whether calcium supplementation prevents preeclampsia, providing 
healthy nutrition for pregnant mothers, including calcium supplementation, is a standard 
of nursing care for this patient population. These suggestions may lead a nurse in a third 
world setting to better prepare for treatment of preeclampsia. 
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